ABSTRACT. Patients with cystic fibrosis have an increased proportion of glycine conjugated bile acids with diminished tauroconjugates which could contribute to fat malabsorption. Twenty-two CF children with documented steatorrhea were supplemented with taurine capsules (30 mg/kg/day) and placebo during separate 6-month treatment periods. Alteration of the glycineltaurine conjugation pattern was verified in two patients who showed a predominance of tauroconjugates as a result of taurine suppiementation. On taurine, steatorrhea was reduced ( p < 0.05) by 17.6 rt 9.7% in 19 patients who completed the study as was the excretion of long-chain saturated fatty acids. There was no change in linoleic acid (C 18:2) excretion. In the 10 patients with a more severe degree of steatorrhea the decrease in fat loss approached 20% and a close relationship was found (r = 0.84, p < 0.01) between the extent of the fatty acid loss on placebo and the decrease of this loss on taurine. A linear relationship was found between the percentage decrease of individual fatty acids and their log solubility in water. No change was found in the daily excretion of bile acids, neutral sterols, and nitrogen. Fasting plasma fatty acids, cholesterol, and triglycerides were also unchanged. Monitoring of growth over the two 6-month periods revealed a marginal ( p < 0
ABSTRACT. Patients with cystic fibrosis have an increased proportion of glycine conjugated bile acids with diminished tauroconjugates which could contribute to fat malabsorption. Twenty-two CF children with documented steatorrhea were supplemented with taurine capsules (30 mg/kg/day) and placebo during separate 6-month treatment periods. Alteration of the glycineltaurine conjugation pattern was verified in two patients who showed a predominance of tauroconjugates as a result of taurine suppiementation. On taurine, steatorrhea was reduced ( p < 0.05) by 17.6 rt 9.7% in 19 patients who completed the study as was the excretion of long-chain saturated fatty acids. There was no change in linoleic acid (C 18:2) excretion. In the 10 patients with a more severe degree of steatorrhea the decrease in fat loss approached 20% and a close relationship was found (r = 0.84, p < 0.01) between the extent of the fatty acid loss on placebo and the decrease of this loss on taurine. A linear relationship was found between the percentage decrease of individual fatty acids and their log solubility in water. No change was found in the daily excretion of bile acids, neutral sterols, and nitrogen. Fasting plasma fatty acids, cholesterol, and triglycerides were also unchanged. Monitoring of growth over the two 6-month periods revealed a marginal ( p < 0.1) increase of weight velocity expressed as a percentage expected for age (83.4 2 11.3 + 117.1 f 16.5). The increase in height velocity in response to taurine showed a more modest trend (95.3 f 7.8 + 110.7 f 10.6). These data provide some support for the use of taurine supplements as an adjuvant form of therapy, particularly in patients with a more severe degree of steatorrhea. Additional clinical testing is warranted before recommending its general use. (Pediatr Res  19: 578-582,1985) Abbreviations CF, cystic fibrosis G/T, glycineltaurine In recent years, taurine has been the subject of increasing interest in view of its role on the developing retina, the central nervous system, liver function, and growth (1-3). There is dietary dependence in so far as man cannot synthesize sufficient amounts to maintain normal levels. It fits the definition of a "conditionally essential" nutrient because needs cannot be met when dietary intake is inadequate or when losses are increased (1 ).
The only well-characterized metabolic reaction of taurine is its conjugation with bile acids in the liver. Conjugation of bile acids is catalyzed by a single enzyme, n-acetyl transferase, which has greater affinity for taurine than for glycine. The percentage of bile acids conjugated with taurine is closely correlated with the hepatic pool of taurine which in turn is dependent on the dietary intake (4). The G/T ratio of conjugated bile acids increases in newborns on taurine-free formulas (5), in patients on TPN (6, 7), short bowel syndrome (8) , and CF (9) .
The increased G/T ratio of bile acids found in CF (9) has been confirmed by others (10, 1 1) and attributed to malabsorption of bile acids. Although fasting (1 1) and postcholecystokynin (10) total duodenal bile acids may be above the critical micellar concentration, it is likely that a significant proportion may not be physiologically available for the micellar solubilization of lipolytic products. Glycoconjugates have a much higher pKa than tauroconjugates (3.8-4.3 versus 1.8) and, therefore, may not remain in micellar solution in the acidic duodenum of patients with pancreatic insufficiency (12) . A further disadvantage of preponderant glycoconjugates with regard to fat absorption is that they are in part passively absorbed in the proximal portion of the absorptive apparatus (1 3, 14) . Since tauroconjugates are mostly absorbed in the ileum (1 3) and are more resistant to bacterial degradation (15) , they are more available to form mixed micelles with fat which may have escaped absorption proximally.
The purpose of this study was to test the hypothesis that the predominance of glycine conjugates with almost complete disappearance of tauroconjugates in certain cases (16) could play a significant role in the fat malabsorption of CF. Herein we report the results of a randomized cross-over trial of taurine supplementation.
PATIENTS AND METHODS
Twenty-two CF children, 14 boys and eight girls, with a mean age of 75/~2 yr (2-16 yr) were admitted to the study on documentation of steatorrhea off pancreatic enzymes (>5 g/24 h). Two patients had hepatomegaly but no echographic evidence of cirrhosis. Bilirubin and aspartate aminotransferase levels were normal; however, seven patients had either a fasting or a 90-min postprandial level of cholylglycine (Radioimmunoassay diagnostic kit, Abbott Laboratories, Ltd., Montreal, Quebec) above 100 pg/dl. The average height as percentage of expected height for age (17) g/24 h and did not differ from the figure of 2.01 2 0.32 g/24 h documented while the subjects were on taurine which contributed only 3.4 mg/kg/day to their daily nitrogen intake.
The total plasma fatty acids (mg/dl) and individual fatty acids, expressed as a percentage of the total, did not differ in the 10 patients who had the most significant degree of steatorrhea. All had detectable amounts of 5,8,1 1 eicosatrienoic acid (C20:3 w9).
Concentrations on taurine (0.46 + 0.04) were the same as on placebo (0.48 -t 0.10). The ratio of C20:3 09 over C20:4 w6 (arachidonic acid) showed no change: it was 0.086 2 0.013 on taurine and 0.088 + 0.0 16 on placebo. Fasting cholesterol and triglyceride levels (mg/dl) were the same on taurine (I 18 rt 4 and 99.4 a 20.7) as on placebo (1 13 + 4 and 78.7 + 9.4).
Of 18 patients in whom growth data were obtained, 1 1 showed an increased weight velocity while only eight showed an improvement in height velocity during the 6-month treatment period with taurine. The average (X rt SE) weight increase, expressed as a percentage of the predicted increase for age, was 117.1 f 16.5 on taurine compared to 83.4 + 11.3 on placebo for the entire group. However, the difference was of borderline significance as the p value was <0.1 (Fig. 3) . Although children on taurine had an average percentage increase of linear growth to 110.7 + 10.6 which was greater than the corresponding figure of 95.3 + 7.8 obtained while they were on placebo there was a wide overlap (Fig. 3) . Further analysis of the data showed that there was no carry over effect of taurine which could have interfered with the growth response to treatment (25) .
DISCUSSION
This study has shown that a taurine supplement of 30 mg/kg/ day administered over 6 months in a two-period single blind cross-over trial had a beneficial effect on fat malabsorption and produced a marginally significant increase in weight velocity.
The experimental protocol preempted a strict double-blind design. During encounters with patients, the first author, P.B.D., was aware of the treatment (placebo or taurine) being given. In that sense it was a single-blind study. However, analysis of growth data and processing of biological samples was canied out in a strict double-blind fashion. The possibility of interaction between treatments which could have affected the results was ruled out by appropriate testing (25) . All patients were evaluated by one of the authors, P.M., prior to entrance into the study. In the majority, the disease was under good control as only two had a
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Shwachman score below 7 1. Although compliance of the 22 children and their families had been predicted to be excellent, three dropped out of the study.
Taurine supplementation in healthy adults led to a reversal of the G/T conjugation ratio or at least to a decrease in the G/T ratio of conjugated bile acids (28, 29) . However, neither of these studies addressed the issue of the physiological implications of shifting the conjugation pattern on fat absorption. On the other hand, two studies conducted in preterm infants showed that adding taurine to formulas to equal concentrations present in human milk failed to improve lipid absorption (5, 42) . Although the change in G/T ratios as a result of taurine supplementation was studied only in two patients, it is reasonable to predict that a change in the conjugation pattern also occurred in the others. It has been shown by Sjovall (29) that the effect of taurine feeding, 1.5-4.5 g/day, was fully apparent within 5 days. The amount administered for 6 months in the present study corresponds to a dosage of more than 2 g/day in adults.
As the study was conducted on an ambulatory basis, no attempt was made to monitor dietary intake of fat. It was assumed that variations would be minimized by using each patient as his own control in a cross-over trial. The majority of patients exhibited a decrease in fat loss. Two important observations were made: first, the degree of improvement brought about by taurine was linearly related to the degree of steatorrhea noted on placebo and, second, the fecal loss of the nonpolar, less soluble fatty acids (long-chain saturates) was more extensively reduced. The findings suggest that a shift in the conjugation pattern probably improved the intraluminal phase of fat digestion. At this juncture it is not possible to say whether it is the lipolytic phase, the micellar dispersion step, or both since they are interdependent and closely interrelated. Bile salts are essential in order for pancreatic lipase to adsorb to the lipid-water interface of the triglyceride droplet. They have "squatter's rights" and will dislodge other surface active dietary constituents such as proteins and clear the surface for the colipase-lipase complex (30) . Bile acids play a central role for the solubilization of lipolytic products. It has been shown that their physicochemical properties determine their physiological function (3 1). Glycine conjugates are capable of dispersing more lipids and have a lower critical micellar concentration than corresponding taurine conjugates. However, these advantages are countered by their tendency to come out of solution in an acidic duodenum and by their greater extent of passive absorption in the jejunum compromising micellar solubilization of lipids distally. The decrease in steatorrhea observed in this study may, therefore,be related to improvement in the formation of micelles which transport products of lipolysis across the unstirred water layer (32). Further indication that taurine favorably affected the shuttle of digested fat between the bulk water phase and the absorptive surface is derived from the data on the fecal sequestration of individual fatty acids. The response to taurine affected mainly the long-chain saturates and was inversely proportional to their water solubility values. The differences between palmitic a.nd linoleic acid in terms of absorbability relates to the lesser availability of the former for incorporation into micelles and to its slower uptake by jejunal absorptive cells (33) .
In contrast to other dietary lipids which undergo chemical changes before forming micelles, the bulk (85-90%) of dietary cholesterol and all of biliary cholesterol are unesterified. Free cholesterol requires the presence of bile salts to overcome the resistance of the unstirred water layer. Bile salts vary in their capacity to promote cholesterol absorption. Dihydroxy bile acids are inferior to the trihydroxy forms in this regard (34) and taur:ine conjugates in vitro are less efficient than glycine conjugates for the solubilization of cholesterol monohydrate (35) . This is perhaps the reason why administration of taurine had no effect on fecal cholesterol excretion. The extent of bile acid loss in ithe stools did not change with taurine. As bile acid loss reflects their rate of synthesis, these data confirm studies in normal adults (28) and in preterm infants (5) . The absence of alterations in the relative proportion of the two primary bile acids and of their respective degradation products suggest that the predominance of taurine conjugates do not bring about selective changes in the pattern of bile salt synthesis or in their extent of microtlial degradation (I 5).
As taurine did not affect the excretion of linoleic or of linoleinic acid, it is not surprising that the plasma fatty acid patterns did not differ. The relative percentage of total plasma fatty acids accounted by C20:3 w9 (5-8-1 1 eicosatrienoic acid) was also unchanged and comparable to other published values in CF on conventional diets (36) . Since it was recently suggested that plasma lipids and lipoproteins are influenced by malabsorption in CF (37), triglycerides and cholesterol were monitored but no difference was observed during treatment with taurine. Neither in adults (38) nor in preterm infants (39) was taurine shown to modify plasma cholesterol levels.
It has been proposed that taurine plays a role as a modulator of growth (1) . Two species of infant primates (cebus and cynomolgus) were shown to depend on a dietary source of taurine ,for maximum growth measured by weight gain (40) . However, these observations remain unexplained since dietary intake and absorption were not examined. In preterm infants, taurine had no effect on growth or on fat absorption (39,4 1) . The only indication that taurine could directly influence growth in man comes from human lymphoblastoid cells cultured in a taurine-supplemeni.ed medium (42) . In the present study, the observation that both mean weight and height velocities, which were below expected values for age during the placebo period, responded to taurine by surpassing expected values is of interest. Should these data which show only a trend be confirmed, one would still have to determine if the growth-promoting effect of taurine is a direct one or is mediated by a decrease in energy loss. In the present study, energy intake was not monitored but questionnaires failed to reveal a change during the two treatment periods and the data show that taurine supplements favored a more complete fat absorption. Although a cause and effect relationship between the fat excretion and the marginal improvement of growth cannot be firmly established, it is the most likely explanation for our findings.
Insufficient food intake in the face of increased requirements imposed by infection and chronic lung disease is now considered the more significant cause of malnutrition in CF (43) . A poor response of the lipolytic phase defect to available pancreatic enzyme supplements (44) and concomitant alterations of bile salt metabolism (9, 45) , compromising micellar solubilization of lipolytic products, are also important factors. Claims of added efficacy of a conventional pancreatic enzyme preparation with added bile salts have not been substantiated (46) . Taurine supplementation appears to be promising as an adjuvant form to therapy, particularly in patients with a significant degree of steatorrhea despite adequate pancreatic supplementation. A better definition of its effects on the absorption of lipids and on the metabolism of bile salts, as well as a clearer demonstration of its repercussions on nutrition and growth, are necessary before recommending its general use.
